Cardiovascular disease in type 2 diabetes mellitus: Current management guidelines

Archives of Internal Medicine

Volumn 163, Issue 1, 2003, Pages 33-40

  Mooradian, Arshag D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; GLYCATION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0037434064     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.1.33     Document Type: Review

References (139)

1. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Diabetes in America, National Diabetes Data Group. 2nd ed. Bethesda, Md: National Institutes of Health; 1995:429-448. NIH publication 95-1468.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;2:434-444.
3. Sprafka JM, Burke GI, Folsom AR, McGovern PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care. 1991;14:537-543.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior history of myocardial infarction. N Engl J Med. 1998; 339:229-234.
5. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291-1297.
6. Feit F, Brooks MM, Sopko G, et al, for the BARI Investigators. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. Circulation. 2000;101:2795-2802.
7. Chaitman BR, Rosen AD, Williams DO, et al. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. Circulation. 1997; 96:2162-2170.
8. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761-1769.
9. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998;32:584-589.
10. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
11. Mooradian AD, Nowak FV. Diabetes mellitus and heart disease. In: Kaiser FE, Morley JE, Coe RM, eds. Cardiovascular Disease in Older Persons. New York, NY: Springer Verlag; 1997:53-72.
12. Mooradian AD, Thurman JE. Glucotoxicity: potential mechanisms. Clin Geriatr Med. 1999;15: 255-263.
13. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
14. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999; 282:1523-1529.
15. Morris RD, Rimm DL, Hartz AJ, Kalkhoff RK, Rimm AA. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32,662 adult white women. Am J Epidemiol. 1989;130:112-121.
16. Bray GA. Obesity increases risk for diabetes. Int J Obes Relat Metab Disord. 1992;16(suppl 4): S13-S17.
17. Felber JP, Acheson KJ, Tappy L. From Obesity to Diabetes. New York, NY: John Wiley & Sons; 1993.
18. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol. 1981;113:144-156.
19. Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985;34:1055-1058.
20. Cassano PA, Rosner B, Vokonas PS, Weiss ST. Obesity and body fat distribution in relation to the incidence of non-insulin-dependent diabetes mellitus: a prospective cohort study of men in the Normative Aging Study. Am J Epidemiol. 1992;136:1474-1486.
21. Bosello O, Zamboni M, Armellini F, Todesco T. Biological and clinical aspects of regional body fat distribution. Diabetes Nutr Metab. 1993;6:163-171.
22. Golditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-486.
23. Chan JM, Rimm EB, Colditz GA, Stampfer JM, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-969.
24. Eckel RH, Krauss RM, for the AHA Nutrition Committee. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation. 1998;97:2099-2100.
25. Mooradian AD. Obesity: a rational target for managing diabetes mellitus. Growth Horm IGF Res. 2001;11(suppl A):S79-S83.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
27. American Diabetes Association. Evidencebased nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002;25:202-212.
28. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN. Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care. 1994;17:30-36.
29. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987;147:1749-1753.
30. Heath GW, Wilson RH, Smith J, Leonard BE. Community-based exercise and weight control: diabetes risk reduction and glycemic control in Zuni Indians. Am J Clin Nutr. 1991;53(suppl): 1642S-1646S.
31. Uusitupa M, Louheranta A, Lindstrom J, et al. The Finnish Diabetes Prevention Study. Br J Nutr. 2000;83(suppl 1):S137-S142.
32. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
33. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001; 24:1957-1960.
34. Heath MJ, Chong E, Weinstein SP, Seaton TB. Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus [abstract]. Diabetes. 1999;48(suppl):A308.
35. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care. 1998;21:1288-1294.
36. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321-1326.
37. Despres J-P, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334: 952-957.
38. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
39. Wannamethee SG, Shaper AG. Type of alcoholic drink and risk of major coronary heart disease events and all-cause mortality. Am J Public Health. 1999;89:685-690.
40. Valmadrid CT, Klein R, Moss SE, Klein BK, Cruickshanks KJ. Alcohol intake and the risk of coronary heart disease mortality in persons with olderonset diabetes mellitus. JAMA. 1999;282:239-246.
41. Solomon CG, Hu FB, Stampfer MJ, et al. Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation. 2000;102:494-499.
42. Ajani UA, Hennekens CH, Spelsberg A, Manson JE. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med. 2000;160:1025-1030.
43. Tanasescu M, Hu FB, Willett WC, Stampfer MJ, Rimm EB. Alcohol consumption and risk of coronary heart disease among men with type 2 diabetes mellitus. J Am Coll Cardiol. 2001;38:1836-1842.
44. Ajani UA, Gaziano M, Lotufo PA, et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation. 2000;102: 500-505.
45. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
46. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
47. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
48. Turner RC, Call CA, Frighi V, Holman RR Jr, for the UKPDS Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
49. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
50. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study: questions answered and issues remaining. Drugs Aging. 2000; 16:159-164.
51. Abraira C, Colwell JA, Nuttall FQ, et al, for the Veterans Affairs Cooperative Study in Type II Diabetes. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM): results of the feasibility trial. Diabetes Care. 1995;18:1113-1123.
52. Malmberg K, for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512-1515.
53. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
54. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-412.
55. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
56. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
57. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs. 1999;57: 19-29.
58. ACE Consensus Conference on Guidelines for Glycemic Control. Endocr Pract. November/December 2001;suppl:2-5.
59. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95-113.
60. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care. 2002;25(suppl 1):S1-S147.
61. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716-730.
62. Chehade JM, Mooradian AD. Drug therapy: current and emerging agents. In: Sinclair AJ, Finucane P, eds. Diabetes in Old Age. 2nd ed. Chichester, England: John Wiley & Sons; 2001: 199-214.
63. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
64. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13:153-169.
65. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
66. Goldberg RB, Mellies MJ, Sacks FM, et al, for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513-2519.
67. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
68. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21:641-648.
69. Effect of fenofibrate on progression of coronaryartery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
70. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
71. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
72. Leitersdorf E. Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. Eur Heart J. 2001;3(suppl E):E17-E23.
73. Elam MB, Hunninghake DB, Davis KB, et al, for the Arterial Disease Multiple Intervention Trial. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA. 2000;284:1263-1270.
74. Mooradian AD, Chehade JM, Thurman JE. The role of thiazolidenediones in the treatment of type 2 diabetes. Treat Endocrinol. 2002;1:13-20.
75. Pearson TA, Laurora I, Chu H, Kfonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
76. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
77. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
78. Curb ID, Pressel SL, Cutler JA, et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
79. Tuomilehto J, Rastenyte D, Birkenhager WH, et al, for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
80. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
81. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
82. Bakris GL, Williams M, Dworkin L, et al, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
83. Ravid M, Savin H, Jutrin I, Dental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensinconverting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118: 577-581.
84. Lacourciere Y, Nadeau A, Poirier L, Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension. 1993;21:786-794.
85. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-860.
86. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
87. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on firstline therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
88. Yusuf S, Gerstein H, Hoogwerf B, for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
89. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
90. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
91. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-652.
92. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
93. Agardh C-D, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 1996;10:185-192.
94. Poulter N, Williams B. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Am J Hypertens. 2001; 14:1170-1172.
95. Sowers JR. Hypertension in type II diabetes: update on therapy. J Clin Hypertens. 1999;1:41-47.
96. Brahmbhat R, Baggaley P, Hockings B. Normalization of blood pressure in a patient with severe orthostatic hypotension and supine hypertension using clonidine [letter]. Hypertension. 2001;37:E24.
97. Cruz DN. Midodrine: a selective α-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin Pharmacother. 2000;1:835-840.
98. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001;17:189-212.
99. Mooradian AD. Micronutrients in diabetes mellitus. In: Ioannides C, Lewis DFV, eds. Drugs, Diet and Disease: Mechanistic Approaches to Diabetes. New York, NY: Ellis Horwood; 1995;2:183-200.
100. Mooradian AD, Failla M, Hoogwerf B, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. Diabetes Care. 1994;17:464-479.
101. Thurman J, Mooradian AD. Vitamin supplementation therapy in the elderly. Drugs Aging. 1997;11:433-449.
102. Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH, et al. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69:261-266.
103. Will JC, Ford ES, Bowman BA. Serum vitamin C concentrations and diabetes: findings from the Third National Health and Nutrition Examination Survey 1988-1994. Am J Clin Nutr. 1999;70:49-52.
104. Mayer-Davis EJ, Bell KA, Reboussin BA, Rushing J, Marshall JA, Hamman RF. Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology. 1998;105:2264-2270.
105. Mayer-Davis EJ, Monaco JH, Marshall JA, Rushing J, Juhaeri J, for the Insulin Resistance Atherosclerosis Study and the San Luis Valley Diabetes Study. Vitamin C intake and cardiovascular disease risk factors in persons with non-insulindependent diabetes mellitus. Prev Med. 1997;26:277-283.
106. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engt J Med. 1996;334:1145-1149.
107. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996;312:478-481.
108. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156-1162.
109. Losonczy KG, Harris TB, Havlik RS. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Population for Epidemiclogic Studies of the Elderly. Am J Clin Nutr. 1996;64:190-196.
110. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139:1180-1189.
111. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
112. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
113. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992;3:194-202.
114. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II: a randomized trial of beta carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000;10:125-134.
115. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P, for the Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
116. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial. Lancet. 1999;354:447-455.
117. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET: the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88:1550-1559.
118. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
119. ATBC (Alpha-Tocopherol, Beta Carotene) Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: the Alpha Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-1035.
120. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
121. Colwell JA. Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:1011-1030.
122. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ (Clin Res Ed). 1988;296:320-331.
123. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
124. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
125. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
126. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996-1003.
127. Ridker PM, Hennekens CH, Buring JE, Rifai N. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
128. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
129. Ridker PM, Rifai N, Clearfield M, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of Creactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
130. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
131. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
132. Ford ES. Body mass index, diabetes, and Creactive protein among US adults. Diabetes Care. 1999;22:1971-1977.
133. Scanu AM. The role of lipoprotein(a) in the pathogenesis of atherosclerotic disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep. 2001;3:385-390.
134. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoprotein A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-1113.
135. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 2001;281:1817-1821.
136. Yeromenko Y, Lavie L, Levy Y. Homocysteine and cardiovascular risk in patients with diabetes mellitus. Nutr Metab Cardiovasc Dis. 2001;11:108-116.
137. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ. 1998;316:894-898.
138. Kind H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
139. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care. 2002;25(suppl1):S64-S68.